| Year |
Citation |
Score |
| 2020 |
D'Angelo CR, Hall A, Woo KM, Kim K, Longo W, Hematti P, Callander N, Kenkre VP, Mattison R, Juckett M. Decitabine induction with myeloablative conditioning and allogeneic hematopoietic stem cell transplantation in high-risk patients with myeloid malignancies is associated with a high rate of infectious complications. Leukemia Research. 96: 106419. PMID 32683127 DOI: 10.1016/J.Leukres.2020.106419 |
0.303 |
|
| 2020 |
Kates AE, Gaulke I, De Wolfe T, Zimbric M, Haight K, Watson L, Suen G, Kim K, Safdar N. Fecal microbiota transplantation for patients on antibiotic treatment with infection history (GRAFT): Study protocol for a phase II, randomized, double-blind, placebo-controlled trial to prevent recurrent infections. Contemporary Clinical Trials Communications. 18: 100576. PMID 32518854 DOI: 10.1016/J.Conctc.2020.100576 |
0.314 |
|
| 2018 |
Albertini MR, Yang RK, Ranheim EA, Hank JA, Zuleger CL, Weber S, Neuman H, Hartig G, Weigel T, Mahvi D, Henry MB, Quale R, McFarland T, Gan J, Carmichael L, ... Kim K, et al. Pilot trial of the hu14.18-IL2 immunocytokine in patients with completely resectable recurrent stage III or stage IV melanoma. Cancer Immunology, Immunotherapy : Cii. PMID 30073390 DOI: 10.1007/S00262-018-2223-Z |
0.346 |
|
| 2017 |
Chang JE, Carmichael LL, Kim K, Peterson C, Yang DT, Traynor AM, Werndli JE, Huie MS, McFarland TA, Volk M, Blank J, Callander NS, Longo WL, Kahl BS. VcR-CVAD Induction Chemotherapy Followed by Maintenance Rituximab Produces Durable Remissions in Mantle Cell Lymphoma: A Wisconsin Oncology Network Study. Clinical Lymphoma, Myeloma & Leukemia. PMID 29191715 DOI: 10.1016/J.Clml.2017.10.006 |
0.305 |
|
| 2017 |
Erbe AK, Wang W, Carmichael L, Kim K, Mendonca EA, Song Y, Hess D, Reville PK, London WB, Naranjo A, Hank JA, Diccianni MB, Reisfeld RA, Gillies SD, Matthay KK, et al. Neuroblastoma Patients' KIR and KIR-ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28972044 DOI: 10.1158/1078-0432.Ccr-17-1767 |
0.325 |
|
| 2017 |
Gee JR, Saltzstein DR, Kim K, Kolesar JM, Huang W, Havighurst TC, Wollmer BW, Stublaski J, Downs T, Mukhtar H, House M, Parnes HL, Bailey HH. A phase II randomized, double-blind, presurgical trial of Polyphenon E in bladder cancer patients to evaluate pharmacodynamics and bladder tissue biomarkers. Cancer Prevention Research (Philadelphia, Pa.). PMID 28325826 DOI: 10.1158/1940-6207.Capr-16-0167 |
0.336 |
|
| 2017 |
Erbe AK, Wang W, Carmichael L, Kim K, Reville PK, London WB, Hank JA, Diccianni MB, Naranjo A, Hogarty M, Park JR, Yu AL, Sondel PM. Abstract LB-048: Impact of KIR/KIR ligand genotype for neuroblastoma patients in a Phase 3 COG immunotherapy trial Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Lb-048 |
0.312 |
|
| 2016 |
Rampurwala M, Wisinski KB, Burkard ME, Ehsani S, O'Regan RM, Carmichael L, Kim K, Kolesar J, Tevaarwerk AJ. Phase 1b study of orteronel in postmenopausal women with hormone-receptor positive (HR+) metastatic breast cancer. Investigational New Drugs. PMID 27826831 DOI: 10.1007/S10637-016-0403-2 |
0.319 |
|
| 2016 |
Chang JE, Havighurst T, Kim K, Eickhoff J, Traynor AM, Kirby-Slimp R, Volk LM, Werndli J, Go RS, Weiss M, Blank J, Kahl BS. Bendamustine + rituximab chemoimmunotherapy and maintenance lenalidomide in relapsed, refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma: A Wisconsin Oncology Network Study. British Journal of Haematology. PMID 26913697 DOI: 10.1111/Bjh.13957 |
0.307 |
|
| 2016 |
Erbe AK, Wang W, Carmichael L, Kim K, Mendonca EA, Song Y, Hess D, London WB, Hank JA, Dicciani MB, Reisfeld RA, Gillies SD, Hogarty MD, Maris JM, Park JR, et al. Impact of KIR/KIR ligand genotype for neuroblastoma patients in a phase III COG immunotherapy trial. Journal of Clinical Oncology. 34: e14014-e14014. DOI: 10.1200/Jco.2016.34.15_Suppl.E14014 |
0.308 |
|
| 2016 |
Chang JE, Peterson C, Carmichael LL, Kim K, Yang DT, Traynor AM, Werndli JE, Huie M, McFarland T, Volk M, Blank JH, Callander NS, Longo WL, Kahl BS. Durable Remissions with the VcR-CVAD Regimen for Mantle Cell Lymphoma (MCL), Regardless of Age: Long-Term Follow-up of a Wisconsin Oncology Network (WON) Study Blood. 128: 149-149. DOI: 10.1182/Blood.V128.22.149.149 |
0.366 |
|
| 2016 |
Jarrard DF, Konety BR, Slaton J, Huang W, Downs T, Kolesar J, Kim K, Havighurst T, House MG, Parnes HL, Bailey HH. MP04-14 PHASE IIA, RANDOMIZED PLACEBO-CONTROLLED TRIAL OF SINGLE HIGH DOSE CHOLECALCIFEROL (VITAMIN D
3
) AND DAILY GENISTEIN (G-2535) VERSUS PLACEBO IN MEN WITH EARLY STAGE PROSTATE CANCER UNDERGOING PROSTATECTOMY Journal of Urology. 195. DOI: 10.1016/J.Juro.2016.02.1949 |
0.3 |
|
| 2015 |
Andreason M, Zhang C, Onitilo AA, Engel J, Ledesma WM, Ridolfi K, Kim K, Charlson JC, Wisinski KB, Tevaarwerk AJ. Treatment differences between urban and rural women with hormone receptor-positive early-stage breast cancer based on 21-gene assay recurrence score result. The Journal of Community and Supportive Oncology. 13: 195-201. PMID 26029936 DOI: 10.12788/Jcso.0135 |
0.306 |
|
| 2015 |
Pak C, Callander NS, Young EW, Titz B, Kim K, Saha S, Chng K, Asimakopoulos F, Beebe DJ, Miyamoto S. MicroC(3): an ex vivo microfluidic cis-coculture assay to test chemosensitivity and resistance of patient multiple myeloma cells. Integrative Biology : Quantitative Biosciences From Nano to Macro. 7: 643-54. PMID 25998180 DOI: 10.1039/C5Ib00071H |
0.316 |
|
| 2015 |
Gee JR, Saltzstein DR, Kim K, Kolesar J, Huang W, Havighurst T, Wollmer BW, Stublaski J, Downs T, Mukhtar H, House M, Parnes H, Bailey H. Abstract A20: A phase II randomized, presurgical placebo-controlled trial of polyphenon E in bladder cancer patients to evaluate bladder tissue levels of EGCG and biomarkers of growth and apoptosis Cancer Prevention Research. 8. DOI: 10.1158/1940-6215.Prev-14-A20 |
0.345 |
|
| 2015 |
Gee J, Saltzstein D, Kim K, Kolesar J, Huang W, Havighurst T, Wollmer B, Stublaski J, Downs T, Mukhtar H, House M, Parnes H, Bailey H. Mp26-01 A Phase Ii Randomized, Presurgical Placebo-Controlled Trial Of Polyphenon E In Bladder Cancer Patients To Evaluate Bladder Tissue Levels Of Egcg And Biomarkers Of Growth And Apoptosis The Journal of Urology. 193. DOI: 10.1016/J.Juro.2015.02.1123 |
0.318 |
|
| 2014 |
Singh CK, Ndiaye MA, Siddiqui IA, Nihal M, Havighurst T, Kim K, Zhong W, Mukhtar H, Ahmad N. Methaneseleninic acid and γ-Tocopherol combination inhibits prostate tumor growth in Vivo in a xenograft mouse model. Oncotarget. 5: 3651-61. PMID 25004451 DOI: 10.18632/Oncotarget.1979 |
0.302 |
|
| 2014 |
Navid F, Sondel PM, Barfield R, Shulkin BL, Kaufman RA, Allay JA, Gan J, Hutson P, Seo S, Kim K, Goldberg J, Hank JA, Billups CA, Wu J, Furman WL, et al. Phase I trial of a novel anti-GD2 monoclonal antibody, Hu14.18K322A, designed to decrease toxicity in children with refractory or recurrent neuroblastoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 1445-52. PMID 24711551 DOI: 10.1200/Jco.2013.50.4423 |
0.301 |
|
| 2014 |
Burkard ME, Wisinski KB, Njiaju UO, Donohue S, Hegeman R, Stella A, Mansky P, Shah V, Goggins T, Qamar R, Dietrich L, Kim K, Traynor AM, Tevaarwerk AJ. Feasibility of 4 cycles of docetaxel and cyclophosphamide every 14 days as an adjuvant regimen for breast cancer: a Wisconsin Oncology Network study. Clinical Breast Cancer. 14: 205-11. PMID 24342730 DOI: 10.1016/J.Clbc.2013.10.018 |
0.356 |
|
| 2014 |
Hoang T, Campbell TC, Zhang C, Kim K, Kolesar JM, Oettel KR, Blank JH, Robinson EG, Ahuja HG, Kirschling RJ, Johnson PH, Huie MS, Wims ME, Larson MM, Hernan HR, et al. Vorinostat and bortezomib as third-line therapy in patients with advanced non-small cell lung cancer: a Wisconsin Oncology Network Phase II study. Investigational New Drugs. 32: 195-9. PMID 23728919 DOI: 10.1007/S10637-013-9980-5 |
0.389 |
|
| 2014 |
Albertini MR, Ranheim E, Hank JA, Zuleger C, McFarland T, Collins J, Clements E, Weber SM, Weigel T, Neuman HB, Hartig GK, Mahvi D, Henry M, Gan J, Yang R, ... Kim K, et al. A pilot trial of hu14.18-IL2 in patients with completely resectable recurrent stage III or stage IV melanoma. Journal of Clinical Oncology. 32: 9044-9044. DOI: 10.1200/Jco.2014.32.15_Suppl.9044 |
0.32 |
|
| 2014 |
Rampurwala MM, Burkard ME, Wisinski KB, Chimeh SE, Zeal J, Koehn T, Champeny TL, Rettig J, Kim K, Kolesar J, Tevaarwerk A. Phase 1b study of orteronel in postmenopausal women with hormone-receptor positive (HR+) metastatic breast cancer. Journal of Clinical Oncology. 32: 538-538. DOI: 10.1200/Jco.2014.32.15_Suppl.538 |
0.322 |
|
| 2014 |
Pak C, Callander NS, Young EW, Titz B, Kim K, Chng K, Miyamoto S, Beebe DJ. Initial Results of an Ex Vivo Microfluidic Cis-Coculture Csra to Predict Response for Myeloma Patients Blood. 124: 4706-4706. DOI: 10.1182/Blood.V124.21.4706.4706 |
0.33 |
|
| 2014 |
Kim K. Randomized Phase II Cancer Clinical Trials by Sin-Ho Jung International Statistical Review. 82: 309-311. DOI: 10.1111/Insr.12068_2 |
0.313 |
|
| 2013 |
Wisinski KB, Faerber A, Wagner S, Havighurst TC, McElroy JA, Kim K, Bailey HH. Predictors of willingness to participate in window-of-opportunity breast trials. Clinical Medicine & Research. 11: 107-12. PMID 23580787 DOI: 10.3121/Cmr.2013.1136 |
0.352 |
|
| 2013 |
Njiaju UO, Tevaarwerk AJ, Kim K, Chang JE, Hansen RM, Champeny TL, Traynor AM, Meadows S, Van Ummersen L, Powers K, Stewart JA. Capecitabine and oxaliplatin in combination as first- or second-line therapy for metastatic breast cancer: a Wisconsin Oncology Network trial. Cancer Chemotherapy and Pharmacology. 71: 613-8. PMID 23228989 DOI: 10.1007/S00280-012-2044-2 |
0.309 |
|
| 2013 |
Grzywacz B, Erbe AK, Wang W, Ranheim EA, Hank JA, Kim K, Carmichael L, Seo S, Mendonca EA, Song Y, Hong F, Gascoyne RD, Paietta E, Horning SJ, Kahl BS, et al. Specific KIR and HLA Genotypes Affect Outcomes Of Single-Agent Anti-CD20 Immunotherapy Of Follicular Lymphoma Blood. 122: 507-507. DOI: 10.1182/Blood.V122.21.507.507 |
0.307 |
|
| 2013 |
Fenske TS, Kim K, Zhang C, Farnen JP, Onitilo AA, Blank JH, Ahuja H, Wassenaar T, Qamar R, Mansky P, Traynor A, Mattison RJ, Kahl BS. Weekly Temsirolimus and Bortezomib For Relapsed Or Refractory B-Cell Non-Hodgkin Lymphoma: A Wisconsin Oncology Network Phase II Study Blood. 122: 3035-3035. DOI: 10.1182/Blood.V122.21.3035.3035 |
0.365 |
|
| 2013 |
Wisinski K, Burkard M, Njiaju U, Donohue S, Hegeman R, Stella A, Mansky P, Shah V, Goggins T, Qamar R, Dietrich L, Kim K, Traynor A, Tevaarwerk A. Abstract P3-12-10: Feasibility of four cycles of docetaxel and cyclophosphamide every 14 days as an adjuvant regimen for breast cancer: A Wisconsin oncology network study Cancer Research. 73. DOI: 10.1158/0008-5472.Sabcs13-P3-12-10 |
0.357 |
|
| 2012 |
Kreul SM, Havighurst T, Kim K, Mendonça EA, Wood GS, Snow S, Borich A, Verma A, Bailey HH. A phase III skin cancer chemoprevention study of DFMO: long-term follow-up of skin cancer events and toxicity. Cancer Prevention Research (Philadelphia, Pa.). 5: 1368-74. PMID 23060038 DOI: 10.1158/1940-6207.Capr-12-0233 |
0.316 |
|
| 2012 |
Frank D, Jumonville A, Loconte NK, Schelman WR, Mulkerin D, Lubner S, Richter K, Winterle N, Wims MB, Dietrich L, Winkler JM, Volk M, Kim K, Holen KD. A phase II study of capecitabine and lapatinib in advanced refractory colorectal adenocarcinoma: A Wisconsin Oncology Network study. Journal of Gastrointestinal Oncology. 3: 90-6. PMID 22811876 DOI: 10.3978/J.Issn.2078-6891.2011.049 |
0.303 |
|
| 2012 |
Albertini MR, Hank JA, Gadbaw B, Kostlevy J, Haldeman J, Schalch H, Gan J, Kim K, Eickhoff J, Gillies SD, Sondel PM. Phase II trial of hu14.18-IL2 for patients with metastatic melanoma. Cancer Immunology, Immunotherapy : Cii. 61: 2261-71. PMID 22678096 DOI: 10.1007/S00262-012-1286-5 |
0.354 |
|
| 2012 |
Messing E, Gee JR, Saltzstein DR, Kim K, diSant'Agnese A, Kolesar J, Harris L, Faerber A, Havighurst T, Young JM, Efros M, Getzenberg RH, Wheeler MA, Tangrea J, Parnes H, et al. A phase 2 cancer chemoprevention biomarker trial of isoflavone G-2535 (genistein) in presurgical bladder cancer patients. Cancer Prevention Research (Philadelphia, Pa.). 5: 621-30. PMID 22293631 DOI: 10.1158/1940-6207.Capr-11-0455 |
0.331 |
|
| 2012 |
Rocque G, Onitilo A, Engel J, Pettke E, Boshoven A, Kim K, Rishi S, Waack B, Wisinski KB, Tevaarwerk A, Burkard ME. Adjuvant therapy for HER2+ breast cancer: practice, perception, and toxicity. Breast Cancer Research and Treatment. 131: 713-21. PMID 22065290 DOI: 10.1007/S10549-011-1862-Y |
0.316 |
|
| 2012 |
Albertini MR, Hank JA, Gadbaw BC, Kostlevy J, Haldeman J, Gan J, Kim K, Eickhoff JC, Gillies S, Sondel PM. Immune monitoring of phase II trial of hu14.18-IL2 for patients with metastatic melanoma. Journal of Clinical Oncology. 30: e19047-e19047. DOI: 10.1200/Jco.2012.30.15_Suppl.E19047 |
0.307 |
|
| 2012 |
Chao BH, Traynor AM, Yang DT, Zhang C, Pier T, Kim K, Rehrauer WM, Cannon DM, Cannon GM, Bye T, Tibbetts RS. Automated quantitative analyses (AQUA) of cyclic-AMP-response-element-binding protein (CREB), phosphorylated CREB (pCREB), and ataxia-telangiectasia-mutated protein kinase (ATM) protein expression in patients (pts) undergoing thoracic radiation for locally advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 30: e13537-e13537. DOI: 10.1200/Jco.2012.30.15_Suppl.E13537 |
0.311 |
|
| 2012 |
Humbert AT, Cook R, McFarland T, Go R, Markovina S, Miyamoto S, Williams EC, Asimakopoulos F, Kolesar J, Thompson MA, Kim K, Callander N. Angiogenic Blockade with Bevacizumab Does Not Increase Response to Lenalidomide and Low Dose Dexamethasone in Relapsed or Refractory Myeloma Blood. 120: 5041-5041. DOI: 10.1182/Blood.V120.21.5041.5041 |
0.337 |
|
| 2012 |
Chang JE, Zhang C, Kim K, Kirby R, Volk L, Werndli J, Go RS, Weiss M, Blank JH, Thompson MA, Farnen JP, Cole CE, Bseiso AW, Volk M, Bayer G, et al. Bendamustine + Rituximab (BR) Chemoimmunotherapy and Maintenance Lenalidomide in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL): A Wisconsin Oncology Network (WON) Study Blood. 120: 3647-3647. DOI: 10.1182/Blood.V120.21.3647.3647 |
0.324 |
|
| 2011 |
Chang JE, Peterson C, Choi S, Eickhoff JC, Kim K, Yang DT, Gilbert LA, Rogers ES, Werndli JE, Huie MS, McFarland TA, Volk M, Blank J, Callander NS, Longo WL, et al. VcR-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin Oncology Network study. British Journal of Haematology. 155: 190-7. PMID 21848883 DOI: 10.1111/J.1365-2141.2011.08820.X |
0.358 |
|
| 2011 |
O'Mahar SE, Campbell TC, Hoang T, Seo S, Kim K, Larson MM, Marcotte SM, LoConte NK, Traynor AM. Phase I study of sunitinib and erlotinib in advanced nonsquamous non-small cell lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 6: 951-3. PMID 21623267 DOI: 10.1097/Jto.0B013E31820Db227 |
0.352 |
|
| 2011 |
Lamont SM, Kim K, Havighurst T, Mendonça E, Wood GS, Snow S, Bailey HH. Abstract A52: A phase III skin cancer chemoprevention study of DFMO in subjects with a history of non-melanoma skin cancer (NMSC): Follow-up of NMSC events greater than 5 years post-study participation Cancer Prevention Research. 4. DOI: 10.1158/1940-6207.Prev-11-A52 |
0.335 |
|
| 2011 |
Rocque G, Onitilo A, Engel J, Pettke E, Boshoven A, Zhang S, Kim K, Rishi S, Waack B, Wisinski K, Tevaarwerk A, Burkard M. P5-18-12: Perception, Practice and Toxicity of Adjuvant Treatment of HER2+ Breast Cancer in Wisconsin. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-P5-18-12 |
0.335 |
|
| 2010 |
Delgado DC, Hank JA, Kolesar J, Lorentzen D, Gan J, Seo S, Kim K, Shusterman S, Gillies SD, Reisfeld RA, Yang R, Gadbaw B, DeSantes KB, London WB, Seeger RC, et al. Genotypes of NK cell KIR receptors, their ligands, and Fcγ receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy. Cancer Research. 70: 9554-61. PMID 20935224 DOI: 10.1158/0008-5472.Can-10-2211 |
0.308 |
|
| 2010 |
Bailey HH, Kim K, Verma AK, Sielaff K, Larson PO, Snow S, Lenaghan T, Viner JL, Douglas J, Dreckschmidt NE, Hamielec M, Pomplun M, Sharata HH, Puchalsky D, Berg ER, et al. A randomized, double-blind, placebo-controlled phase 3 skin cancer prevention study of {alpha}-difluoromethylornithine in subjects with previous history of skin cancer. Cancer Prevention Research (Philadelphia, Pa.). 3: 35-47. PMID 20051371 DOI: 10.1158/1940-6207.Capr-09-0096 |
0.314 |
|
| 2010 |
Frank DJ, LoConte NK, Brooks W, Kim K, Mulkerin D, Schelman WR, Jumonville A, Holen KD. A phase II trial of lapatinib and capecitabine for patients with refractory advanced colorectal adenocarcinoma. Journal of Clinical Oncology. 28: e14092-e14092. DOI: 10.1200/Jco.2010.28.15_Suppl.E14092 |
0.355 |
|
| 2009 |
Callander NS, Markovina S, Juckett MB, Wagner E, Kolesar J, Longo W, Williams EC, Kim K, Werndli J, Miyamoto S. The Addition of Bevacizumab (B) to Lenalidomide and Low Dose Dexamethasone Does Not Significantly Increase Response in Relapsed or Refractory Multiple Myeloma (NCI#7317). Blood. 114: 3885-3885. DOI: 10.1182/Blood.V114.22.3885.3885 |
0.348 |
|
| 2008 |
Chang JE, Medlin SC, Kahl BS, Longo WL, Williams EC, Lionberger J, Kim K, Kim J, Esterberg E, Juckett MB. Augmented and standard Berlin-Frankfurt-Munster chemotherapy for treatment of adult acute lymphoblastic leukemia. Leukemia & Lymphoma. 49: 2298-307. PMID 19052977 DOI: 10.1080/10428190802517732 |
0.338 |
|
| 2008 |
Attia S, Traynor AM, Kim K, Merchant JJ, Hoang T, Ahuja HG, Beatty PA, Hansen RM, Masters GA, Oettel KR, Shapiro GR, Larson MM, Larson ML, Schiller JH. Phase I/II study of vinorelbine and exisulind as first-line treatment of advanced non-small cell lung cancer in patients at least 70 years old: a wisconsin oncology network study. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 3: 1018-25. PMID 18758305 DOI: 10.1097/Jto.0B013E3181834Fa1 |
0.376 |
|
| 2008 |
Petrich A, Kahl B, Bailey H, Kim K, Turman N, Juckett M. Phase II study of doxercalciferol for the treatment of myelodysplastic syndrome. Leukemia & Lymphoma. 49: 57-61. PMID 18203012 DOI: 10.1080/10428190701713648 |
0.336 |
|
| 2006 |
Hoang T, Kim K, Merchant J, Traynor AM, McGovern J, Oettel KR, Sanchez FA, Ahuja HG, Hensing TA, Larson M, Schiller JH. Phase I/II study of gemcitabine and exisulind as second-line therapy in patients with advanced non-small cell lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 1: 218-25. PMID 17409860 DOI: 10.1016/S1556-0864(15)31571-9 |
0.353 |
|
| 2006 |
Dixon DO, Freedman RS, Herson J, Hughes M, Kim K, Silverman MH, Tangen CM. Guidelines for data and safety monitoring for clinical trials not requiring traditional data monitoring committees. Clinical Trials (London, England). 3: 314-9. PMID 16895048 DOI: 10.1191/1740774506Cn149Oa |
0.312 |
|
| 2005 |
Walker L, Schalch H, King DM, Dietrich L, Eastman M, Kwak M, Kim K, Albertini MR. Phase II trial of weekly paclitaxel in patients with advanced melanoma. Melanoma Research. 15: 453-9. PMID 16179874 DOI: 10.1097/00008390-200510000-00015 |
0.365 |
|
| 2005 |
Morgan-Meadows S, Mulkerin D, Berlin JD, Kim K, Bailey H, Saphner T, Jumonville A, Hansen R, Ahuja H, McFarland T, Thomas JP. A phase II trial of gemcitabine, 5-fluorouracil and leucovorin in advanced esophageal carcinoma. Oncology. 69: 130-4. PMID 16118509 DOI: 10.1159/000087815 |
0.343 |
|
| 2005 |
Kahl BS, Bailey HH, Smith EP, Turman N, Smith J, Werndli J, Williams EC, Longo WL, Kim K, Mcgovern J, Jumonville A. Phase II study of weekly low-dose paclitaxel for relapsed and refractory non-Hodgkin's lymphoma: a Wisconsin Oncology Network Study. Cancer Investigation. 23: 13-18. DOI: 10.1081/Cnv-46484 |
0.371 |
|
| 2004 |
Jung SH, Lee T, Kim K, George SL. Admissible two-stage designs for phase II cancer clinical trials. Statistics in Medicine. 23: 561-9. PMID 14755389 DOI: 10.1002/Sim.1600 |
0.305 |
|
| 2004 |
Kahl BS, Ahuja HG, Sanchez FA, Rodrigues GA, Voorhees PM, Stevens EA, Smith J, Turman N, Kim K, Bailey HH. Phase II Study of Arsenic Trioxide Plus Ascorbic Acid for Relapsed and Refractory Lymphoid Malignancies: A Wisconsin Oncology Network Study. Blood. 104: 4582-4582. DOI: 10.1182/Blood.V104.11.4582.4582 |
0.358 |
|
| 2003 |
Hoang T, Kim K, Jaslowski A, Koch P, Beatty P, McGovern J, Quisumbing M, Shapiro G, Witte R, Schiller JH. Phase II study of second-line gemcitabine in sensitive or refractory small cell lung cancer. Lung Cancer (Amsterdam, Netherlands). 42: 97-102. PMID 14512193 DOI: 10.1016/S0169-5002(03)00273-3 |
0.376 |
|
| 2001 |
Leu KM, Kim K, Larson M, Larson M, Schiller JH. Phase I/II trial of docetaxel and vinorelbine in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy Lung Cancer. 34: 105-113. PMID 11557120 DOI: 10.1016/S0169-5002(01)00209-4 |
0.378 |
|
| 2000 |
Merchant JJ, Kim K, Mehta MP, Ripple GH, Larson ML, Brophy DJ, Hammes LC, Schiller JH. Pilot and safety trial of carboplatin, paclitaxel, and thalidomide in advanced non small-cell lung cancer. Clinical Lung Cancer. 2: 48-52; discussion 53. PMID 14731337 DOI: 10.3816/Clc.2000.N.017 |
0.366 |
|
| 2000 |
Robles C, Kim KM, Oken MM, Bennett JM, Letendre L, Wiernik PH, O'Connell MJ, Cassileth PA. Low-dose cytarabine maintenance therapy vs observation after remission induction in advanced acute myeloid leukemia: an Eastern Cooperative Oncology Group Trial (E5483). Leukemia. 14: 1349-53. PMID 10942228 DOI: 10.1038/Sj.Leu.2401850 |
0.363 |
|
| 1999 |
Turrisi AT, Kim K, Blum R, Sause WT, Livingston RB, Komaki R, Wagner H, Aisner S, Johnson DH. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. The New England Journal of Medicine. 340: 265-71. PMID 9920950 DOI: 10.1056/Nejm199901283400403 |
0.348 |
|
| 1998 |
Chang AY, Kim K, Boucher H, Bonomi P, Stewart JA, Karp DD, Blum RH. A randomized phase II trial of echinomycin, trimetrexate, and cisplatin plus etoposide in patients with metastatic nonsmall cell lung carcinoma: An Eastern Cooperative Oncology Group study (E1587) Cancer. 82: 292-300. PMID 9445185 DOI: 10.1002/(Sici)1097-0142(19980115)82:2<301::Aid-Cncr8>3.0.Co;2-T |
0.378 |
|
| 1997 |
Roberts JA, Jenison EL, Kim K, Clarke-Pearson D, Langleben A. A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Dose-Finding Study of ORG 2766 in the Prevention or Delay of Cisplatin-Induced Neuropathies in Women with Ovarian Cancer Gynecologic Oncology. 67: 172-177. PMID 9367703 DOI: 10.1006/Gyno.1997.4832 |
0.322 |
|
| 1997 |
Loehrer PJ, Chen M, Kim K, Aisner SC, Einhorn LH, Livingston R, Johnson D. Cisplatin, doxorubicin, and cyclophosphamide plus thoracic radiation therapy for limited-stage unresectable thymoma: an intergroup trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 15: 3093-9. PMID 9294472 DOI: 10.1200/Jco.1997.15.9.3093 |
0.303 |
|
| 1996 |
Schiller JH, Kim K, Hutson P, DeVore R, Glick J, Stewart J, Johnson D. Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 14: 2345-52. PMID 8708727 DOI: 10.1200/Jco.1996.14.8.2345 |
0.362 |
|
| 1994 |
Loehrer PJ, Kim K, Aisner SC, Livingston R, Einhorn LH, Johnson D, Blum R. Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 12: 1164-8. PMID 8201378 DOI: 10.1200/Jco.1994.12.6.1164 |
0.349 |
|
| 1993 |
Chang AY, Kim K, Glick J, Anderson T, Karp D, Johnson D. Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: The Eastern Cooperative Oncology Group Results. Journal of the National Cancer Institute. 85: 388-94. PMID 8094467 DOI: 10.1093/Jnci/85.5.388 |
0.388 |
|
| 1992 |
Hochster HS, Kim K, Green MD, Mann RB, Neiman RS, Oken MM, Cassileth PA, Stott P, Ritch P, O'Connell MJ. Activity of fludarabine in previously treated non-Hodgkin's low-grade lymphoma: results of an Eastern Cooperative Oncology Group study. Journal of Clinical Oncology. 10: 28-32. PMID 1727921 DOI: 10.1200/Jco.1992.10.1.28 |
0.345 |
|
| 1992 |
Kim K. Study duration for group sequential clinical trials with censored survival data adjusting for stratification Statistics in Medicine. 11: 1477-1488. PMID 1329172 DOI: 10.1002/Sim.4780111106 |
0.336 |
|
| 1991 |
Cummings FJ, Kim K, Neiman RS, Comis RL, Oken MM, Weitzman SA, Mann RB, O'Connell MJ. Phase II trial of pentostatin in refractory lymphomas and cutaneous T-cell disease. Journal of Clinical Oncology. 9: 565-571. PMID 2066753 DOI: 10.1200/Jco.1991.9.4.565 |
0.331 |
|
| 1990 |
Kim K, Tsiatis AA. Study duration for clinical trials with survival response and early stopping rule Biometrics. 46: 81-92. PMID 2350572 DOI: 10.2307/2531632 |
0.329 |
|
| Show low-probability matches. |